Compounds > raloxifene hydrochloride
Page last updated: 2024-08-23

raloxifene hydrochloride and 2019 Novel Coronavirus Disease

raloxifene hydrochloride has been researched along with 2019 Novel Coronavirus Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (100.00)2.80

Authors

AuthorsStudies
Bram, Y; Chen, S; Copertino, DC; Duarte, RRR; Han, Y; Iñiguez, LP; Marston, JL; Nixon, DF; Powell, TR; Schwartz, RE1
Belli, S; Caruso, F; Florea, RM; Incerpi, S; Kaur, S; Pedersen, JZ; Rossi, M1
Chang, J; Im, S; Jeon, S; Jeong, K; Jo, Y; Kim, DH; Kim, J; Kim, KC; Kim, S; Kim, YE; Lee, H; Lee, JC; Lee, JY; Lee, W; Min, JY; Nam, TG; Noh, H; On, DI; Park, HJ; Park, JW; Park, SM; Seok, SH; Seong, JK; Song, D; Yeom, M; Yun, JW1
Bauer, DC; Clarke, BL; Drake, MT; Tsourdi, E; Yu, EW1
Alfadhli, EM1

Reviews

1 review(s) available for raloxifene hydrochloride and 2019 Novel Coronavirus Disease

ArticleYear
Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic.
    Clinical therapeutics, 2021, Volume: 43, Issue:4

    Topics: Bone Density; Calcium; Cinacalcet; COVID-19; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Middle Aged; Parathyroidectomy; Raloxifene Hydrochloride; Vitamin D

2021

Other Studies

4 other study(ies) available for raloxifene hydrochloride and 2019 Novel Coronavirus Disease

ArticleYear
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
    Molecular medicine (Cambridge, Mass.), 2021, 09-09, Volume: 27, Issue:1

    Topics: Antiviral Agents; Atorvastatin; Cell Line; Coronavirus 3C Proteases; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Doxycycline; Drug Approval; Drug Repositioning; Gene Expression Regulation; Humans; Lung; Models, Biological; Molecular Docking Simulation; Organoids; Raloxifene Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Trifluoperazine; United States; United States Food and Drug Administration; Vesiculovirus; Virus Internalization

2021
Mechanism of Caspase-1 Inhibition by Four Anti-inflammatory Drugs Used in COVID-19 Treatment.
    International journal of molecular sciences, 2022, Feb-06, Volume: 23, Issue:3

    Topics: Anti-Inflammatory Agents; Caspase 1; Caspase Inhibitors; Colchicine; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Models, Molecular; Molecular Docking Simulation; Pentacyclic Triterpenes; Protein Interaction Domains and Motifs; Raloxifene Hydrochloride; Viral Protease Inhibitors

2022
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
    Antiviral research, 2023, Volume: 209

    Topics: Antiviral Agents; COVID-19; Humans; Luminescence; Middle East Respiratory Syndrome Coronavirus; Raloxifene Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus

2023
Osteoporosis Management in the Era of COVID-19.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020, Volume: 35, Issue:6

    Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Continuity of Patient Care; Coronavirus Infections; COVID-19; Denosumab; Disease Management; Drug Administration Schedule; Estrogen Replacement Therapy; Fractures, Spontaneous; Home Care Services; Humans; Immunosuppression Therapy; Osteoporosis; Pandemics; Pneumonia, Viral; Raloxifene Hydrochloride; Recurrence; Telemedicine; Thrombophilia; Unnecessary Procedures

2020